What is the role of hormone therapy in the prevention of postmenopausal osteoporosis?

What is the role of hormone therapy in the prevention of postmenopausal osteoporosis?

• A. Hormone therapy is not effective for prevention.
• B. Hormone therapy is first-line for osteoporosis treatment.
• C. Hormone therapy is effective for prevention of bone loss in early postmenopausal women at risk, but not first-line for osteoporosis treatment.
• D. Hormone therapy cures osteoporosis.

Answer: (C)

Estrogen helps protect bone by reducing the very high bone turnover that follows menopause. When started in women who are early in the postmenopausal period and at risk for rapid bone loss, hormone therapy can effectively prevent further bone loss and help preserve bone mineral density, which may lower fracture risk in that window. However, it is not used as the first-line treatment for established osteoporosis because long-term use carries risks such as blood clots, stroke, and cancer signals (varying by uterus status and regimen). For ongoing fracture prevention in established osteoporosis, safer, more targeted therapies like bisphosphonates or denosumab are preferred. Hormone therapy is not a cure for osteoporosis; it can slow loss and support density in the right context, but other osteoporosis medications are generally needed for long-term fracture risk reduction. It may be considered briefly to prevent bone loss in early postmenopause, especially if vasomotor symptoms are also present, and then discontinued in favor of non-hormonal osteoporosis treatments.

Estrogen helps protect bone by reducing the very high bone turnover that follows menopause. When started in women who are early in the postmenopausal period and at risk for rapid bone loss, hormone therapy can effectively prevent further bone loss and help preserve bone mineral density, which may lower fracture risk in that window.

However, it is not used as the first-line treatment for established osteoporosis because long-term use carries risks such as blood clots, stroke, and cancer signals (varying by uterus status and regimen). For ongoing fracture prevention in established osteoporosis, safer, more targeted therapies like bisphosphonates or denosumab are preferred. Hormone therapy is not a cure for osteoporosis; it can slow loss and support density in the right context, but other osteoporosis medications are generally needed for long-term fracture risk reduction. It may be considered briefly to prevent bone loss in early postmenopause, especially if vasomotor symptoms are also present, and then discontinued in favor of non-hormonal osteoporosis treatments.